Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy
文献类型：期刊论文
| 作者 | Zhang, Xu1,2; Wang, Yuxiang2; Meng, Linghua1,2
|
| 刊名 | ACTA PHARMACEUTICA SINICA B
 |
| 出版日期 | 2022-03-01 |
| 卷号 | 12期号:3页码:1054-1067 |
| 关键词 | Esophageal cancer Esophageal squamous cell carcinoma Esophageal adenocarcinoma Next-generation sequencing Genomic alteration Somatic mutation Copy number variation Molecularly targeted therapy |
| ISSN号 | 2211-3835 |
| DOI | 10.1016/j.apsb.2021.09.028 |
| 通讯作者 | Meng, Linghua(lhmeng@simm.ac.cn) |
| 英文摘要 | Esophageal cancer is one of the most lethal cancers worldwide because of its rapid progression and poor prognosis. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are two major subtypes of esophageal cancer. ESCC predominantly affects African and Asian populations, which is closely related to chronic smoking and alcohol consumption. EAC typically arises in Barrett's esophagus with a predilection for Western countries. While surgical operation and chemoradiotherapy have been applied to combat this deadly cancer, molecularly targeted therapy is still at the early stages. With the development of large-scale next-generation sequencing, various genomic alterations in ESCC and EAC have been revealed and their potential roles in the initiation and progression of esophageal cancer have been studied. Potential therapeutic targets have been identified and novel approaches have been developed to combat esophageal cancer. In this review, we comprehensively analyze the genomic alterations in EAC and ESCC and summarize the potential role of the genetic alterations in the development of esophageal cancer. Progresses in the therapeutics based on the different tissue types and molecular signatures have also been reviewed and discussed. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. |
| WOS关键词 | GROWTH-FACTOR RECEPTOR ; GENE AMPLIFICATION ; TUMOR-SUPPRESSOR ; CYCLIN D1 ; PHASE-II ; C-MYC ; BARRETTS-ESOPHAGUS ; SIGNALING PATHWAY ; POOR-PROGNOSIS ; EXPRESSION |
| 资助项目 | National Natural Science Foundation of China[81973345] ; National Natural Science Foundation of China[82173832] ; Chinese Academy of Sciences (China)[XDA12020111] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000779794500004 |
| 出版者 | INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/299833]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Meng, Linghua |
| 作者单位 | 1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhang, Xu,Wang, Yuxiang,Meng, Linghua. Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy[J]. ACTA PHARMACEUTICA SINICA B,2022,12(3):1054-1067. |
| APA | Zhang, Xu,Wang, Yuxiang,&Meng, Linghua.(2022).Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy.ACTA PHARMACEUTICA SINICA B,12(3),1054-1067. |
| MLA | Zhang, Xu,et al."Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy".ACTA PHARMACEUTICA SINICA B 12.3(2022):1054-1067. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。